Anti-Therapeutic Action: Reduced susceptibility to azoles

Candida vulturna, the Next Fungal Menace? A Narrative Review

mycolabadmin

Candida vulturna is a newly discovered yeast that causes serious blood infections, particularly in vulnerable patients like premature infants and those with cancer. Though still rare, cases are increasingly appearing in tropical regions with documented hospital outbreaks. While the infection has a better survival rate than related species, it resists several common antifungal drugs, making treatment challenging and requiring careful use of remaining effective medications.

Read More »

Epidemiology of Candidemia, Candiduria and Emerging Candidozyma (Candida) auris Across Gulf Cooperative Council Countries and Yemen in the Arabian Peninsula

mycolabadmin

This comprehensive review examines fungal bloodstream and urinary tract infections caused by Candida species across Middle Eastern countries. The study shows that while Candida albicans remains common, dangerous antibiotic-resistant strains like Candidozyma auris are increasingly appearing in hospitals. The research highlights that better diagnostic tools and infection prevention practices are urgently needed in the region to protect patients and reduce deaths from these serious infections.

Read More »

Genomic Insights of Candida krusei, an Emerging Fungal Pathogen With Intrinsic Antifungal Resistance

mycolabadmin

Candida krusei is a yeast that causes serious bloodstream infections, particularly in people with weakened immune systems. Unlike many other fungi, it naturally resists common antifungal drugs like fluconazole, making infections hard to treat. The organism can form protective biofilms and has multiple genetic mechanisms that help it survive antifungal treatment. Researchers are exploring new drugs and treatment strategies to combat this growing health threat, especially in hospitals.

Read More »

Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte, Trichophyton indotineae

mycolabadmin

A new type of fungal infection called Trichophyton indotineae has emerged and spread globally, particularly from India. It causes widespread skin infections that are difficult to treat because the fungus resists common antifungal medications. Doctors and laboratories need to be aware of this infection to properly identify it and choose effective treatments, especially for patients with travel history to affected regions.

Read More »

Evaluation of Antifungal Activity Against Candida albicans Isolates From HIV-Positive Patients with Oral Candidiasis in a Major Referral Hospital, West Java, Indonesia

mycolabadmin

This study examined fungal infections in HIV-positive patients’ mouths at an Indonesian hospital. Researchers identified which Candida species caused the infections and tested how well common antifungal medications worked against them. They found that while a specific antifungal drug (fluconazole) was effective in most cases, some infections showed resistance, suggesting the need for careful monitoring and personalized treatment approaches.

Read More »
Scroll to Top